Media Coverage

Klox secures positive top-line results, in commercial discussions


Jul 03, 2018 - Animal Pharm
By Joseph Harvey
Animal Pharm
July 3, 2018


Klox Technologies has recorded encouraging results from a pivotal study of Phovia, which is being developed for the management of canine deep pyoderma (CDP).

The 80-patient study "met all endpoints and demonstrated Phovia significantly reduces time to clinical resolution, while reducing the duration of antibiotic use". It took place at the University of Camerino in Italy.

Phovia is a topical fluorescence biomodulating product designed to stimulate canine biological systems. The product consists of a hand-held LED lamp and a topical gel with light capturing molecules called chromophores. Once the gel is activated by the LED lamp, it emits hyper-pulsed multi-wavelength fluorescent light.

The study was randomized, controlled and blinded. It compared the current standard-of-care (systemic antibiotic therapy) with the standard-of-care plus a twice-weekly treatment with Phovia, until clinical resolution was achieved.

Dublin-based Klox stated: "Phovia demonstrated efficacy for the primary endpoint, with the proportion of patients reaching clinical resolution at six weeks being 26.5% for the control group and 84.6% for the Phovia treated group. The statistically significant differences between the two groups were obtained as soon as week three.

"For the secondary endpoints, the Phovia-treated group showed a statistically significant reduction of clinical scores, and an improvement in neutrophil engulfing bacteria scores. An exploratory endpoint demonstrated the median time to clinical resolution for the control group was 12.7 weeks while the Phovia treated group was four weeks – a significant reduction in treatment times. No product-related adverse events were recorded."

The company's head of animal health Ricardo Garvao told Animal Pharm: "These are quite spectacular results showing the product can reduce the time to healing of severe deep pyodermas from about 12 weeks to four weeks, also reducing by the same amount the exposure to systemic antibiotics."

Klox is in discussions with potential commercial partners for Phovia, which should hit the European market in the first half of 2019. The firm said these negotiations also include its pipeline products. A partnership is expected to be announced later this year.

Elsewhere, Klox has started to investigate the ability of its phototherapy to break down biofilms in pathogens isolated from cases of canine otitis externa.

Dr Garvao said the company has other projects in the pipeline but at an earlier stage of development than its work in CDP and otitis externa.

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum